Active Ingredient History
Valproic acid (VPA; valproate; di-n-propylacetic acid, DPA; 2-propylpentanoic acid, or 2-propylvaleric acid) was first synthesized in 1882, by Burton. FDA approved valproic acid for the treatment of manic episodes associated with bipolar disorder, for the monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures and adjunctive therapy in patients with multiple seizure types that include absence seizures and for the prophylaxis of migraine headaches. The mechanisms of VPA which seem to be of clinical importance in the treatment of epilepsy include increased gamma-aminobutyric acid (GABA)-ergic activity, reduction in excitatory neurotransmission, and modification of monoamines. Recently, it was discovered that the VPA is a class I selective histone deacetylase inhibitor. This activity can be distinguished from its therapeutically exploited antiepileptic activity. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Migraine Disorders (approved 2008)
Acute Kidney Injury (Phase 4)
Alcohol Drinking (Phase 4)
Alcoholism (Phase 4)
Alcohol-Related Disorders (Phase 2/Phase 3)
Alcohol Withdrawal Delirium (Phase 4)
Alopecia (Phase 2)
Alopecia Areata (Early Phase 1)
Alzheimer Disease (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 3)
Antipsychotic Agents (Phase 2/Phase 3)
Anxiety (Phase 3)
Anxiety Disorders (Phase 4)
Asthma (Phase 4)
Astrocytoma (Phase 3)
Autism Spectrum Disorder (Phase 2)
Autistic Disorder (Phase 4)
Autoimmune Lymphoproliferative Syndrome (Phase 1/Phase 2)
Bariatric Surgery (Phase 4)
Behavioral Symptoms (Phase 4)
Bone Diseases, Metabolic (Phase 4)
Brain Injuries (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Brain Ischemia (Phase 4)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 1)
Carcinoma (Phase 1)
Carcinoma, Mucoepidermoid (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 1)
Castleman Disease (Phase 1)
Cocaine-Related Disorders (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Coma (Phase 4)
Conduct Disorder (Phase 4)
Contraception (Phase 1)
Coronary Artery Disease (Phase 1/Phase 2)
COVID-19 (Phase 4)
Craniocerebral Trauma (Phase 3)
Delirium (Phase 4)
Dementia (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Diffuse Intrinsic Pontine Glioma (Phase 3)
Digestive System Neoplasms (Phase 1)
Drug Interactions (Phase 1)
Drug Resistant Epilepsy (Phase 4)
Drugs, Investigational (Phase 3)
Ependymoma (Phase 2/Phase 3)
Epilepsies, Partial (Phase 4)
Epilepsy ()
Epilepsy, Absence (Phase 3)
Epilepsy, Post-Traumatic (Phase 3)
Epilepsy, Reflex (Phase 4)
Erdheim-Chester Disease (Phase 1)
Eye Diseases (Phase 2)
Eye Diseases, Hereditary (Phase 2)
Glioblastoma (Phase 3)
Glioma (Phase 4)
Gliosarcoma (Phase 2)
Glomerulosclerosis, Focal Segmental (Phase 2/Phase 3)
Glycogen Storage Disease Type V (Phase 2)
Graft vs Host Disease (Phase 2)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 4)
Heart Arrest (Phase 4)
Heart Valve Diseases (Phase 1/Phase 2)
Hematologic Neoplasms (Phase 1)
Hematuria (Early Phase 1)
Hemorrhage (Phase 4)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 1)
Huntington Disease (Phase 2)
Hypersplenism (Phase 1/Phase 2)
Hypoxia, Brain (Phase 4)
Hypoxia-Ischemia, Brain (Phase 4)
Intellectual Disability (Phase 4)
Intracranial Hemorrhages (Phase 4)
Irritable Mood (Phase 4)
Ischemic Stroke (Phase 2)
Kidney Diseases (Phase 2/Phase 3)
Lamotrigine (Phase 4)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Diseases (Phase 1)
Lung Neoplasms (Phase 1/Phase 2)
Lymphadenopathy (Phase 1/Phase 2)
Lymphangioleiomyomatosis (Phase 1)
Lymphoma (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Mania (Phase 4)
Marijuana Abuse (Phase 3)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Migraine Disorders (Phase 4)
Migraine with Aura (Phase 3)
Migraine without Aura (Phase 3)
Mood Disorders (Phase 4)
Mouth Neoplasms (Phase 2)
Multiple Organ Failure (Phase 1/Phase 2)
Muscular Atrophy, Spinal (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Neoplasm Metastasis (Phase 1/Phase 2)
Neoplasms (Phase 2)
Neoplasms, Adnexal and Skin Appendage (Phase 1)
Neoplasms, Mesothelial (Phase 1)
Neoplasms, Neuroepithelial (Phase 3)
Nephrosis, Lipoid (Phase 2/Phase 3)
Neuralgia (Phase 2/Phase 3)
Neuroblastoma (Phase 1)
Neuroectodermal Tumors (Phase 1)
Neurofibromatosis 2 (Phase 1)
Nodding Syndrome (Phase 2)
Obesity (Phase 4)
Opioid-Related Disorders (Phase 4)
Oropharyngeal Neoplasms (Phase 2)
Osteoporosis (Phase 4)
Ovarian Neoplasms (Phase 3)
Pain (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 2)
Panic Disorder (Phase 4)
Paraparesis, Tropical Spastic (Phase 3)
Persistent Vegetative State (Phase 4)
Phantom Limb (Phase 2)
Pharmacokinetics (Phase 4)
Phobia, Social (Phase 2)
Pneumonia, Viral (Phase 4)
Precancerous Conditions (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 2)
Psychomotor Agitation (Phase 3)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Pulmonary Arterial Hypertension (Phase 2)
Rectal Neoplasms (Phase 2)
Renal Insufficiency (Phase 4)
Reperfusion Injury (Phase 2)
Retinal Degeneration (Phase 2)
Retinal Diseases (Phase 2)
Retinitis Pigmentosa (Phase 2)
Rubinstein-Taybi Syndrome (Phase 2)
Sarcoma (Phase 1/Phase 2)
Schizophrenia (Phase 4)
Scleroderma, Systemic (Phase 1/Phase 2)
Seizures (Phase 3)
Shock, Hemorrhagic (Phase 1)
Small Cell Lung Carcinoma (Phase 2)
Soft Tissue Neoplasms (Phase 1)
Spasms, Infantile (Phase 2)
Spinal Muscular Atrophies of Childhood (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Status Epilepticus (Phase 3)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Phase 4)
Substance Withdrawal Syndrome (Phase 4)
Supranuclear Palsy, Progressive (Phase 2)
Thrombosis (Phase 1)
Thyroid Neoplasms (Phase 2)
Toxoplasmosis (Phase 4)
Urinary Bladder Neoplasms (Early Phase 1)
Uterine Cervical Neoplasms (Phase 3)
Wolfram Syndrome (Phase 2)
Work of Breathing (Phase 1)
Wounds and Injuries (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
